IDEAYA Biosciences Inc
For the period ended Dec 31, 2023. Filed Feb 20, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 20, 2024
IDYA$32.03+2.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets
(in thousands, except share and per share amounts)
| December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $157,018 | $68,632 |
| Short-term marketable securities | 368,096 | 296,197 |
| Accounts receivable | 18 | 211 |
| Prepaid expenses and other current assets | 7,500 | 5,414 |
| Total current assets | 532,632 | 370,454 |
| Restricted cash | 757 | 106 |
| Long-term marketable securities | 107,492 | 8,317 |
| Property and equipment, net | 6,164 | 6,509 |
| Right-of-use assets | 2,246 | 2,484 |
| Other non-current assets | 25 | 99 |
| Total assets | $649,316 | $387,969 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities | ||
| Accounts payable | $6,598 | $4,280 |
| Accrued liabilities | 18,756 | 16,999 |
| Contract liability | — | 8,568 |
| Operating lease liabilities, current | 1,747 | 1,871 |
| Total current liabilities | 27,101 | 31,718 |
| Long-term contract liability | — | 5,185 |
| Long-term operating lease liabilities | 1,125 | 1,611 |
| Total liabilities | 28,226 | 38,514 |
| Commitments and contingencies (Note 6) | ||
| Stockholders’ equity | ||
| Preferred stock, $0.0001 par value, 10,000,000 shares authorized as of December 31, 2023 and December 31, 2022; no shares issued and outstanding as of December 31, 2023 and December 31, 2022 | — | — |
| Common stock, $0.0001 par value, 300,000,000 shares authorized as of December 31, 2023 and December 31, 2022; 65,039,369 and 48,193,179 shares issued and outstanding as of December 31, 2023 and December 31, 2022 | 7 | 5 |
| Additional paid-in capital | 968,885 | 587,724 |
| Accumulated other comprehensive income (loss) | 562 | (2,871) |
| Accumulated deficit | (348,364) | (235,403) |
| Total stockholders’ equity | 621,090 | 349,455 |
| Total liabilities and stockholders’ equity | $649,316 | $387,969 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.